☰

Lori R. Rink, Ph.D. - Publications

Affiliations: 
2006 Temple University, Philadelphia, PA, United States 
Area:
Oncology, Molecular Biology, Cell Biology
Tree Info Similar researchers PubMed Report error

10 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Kozinova M, Joshi S, Ye S, Belinsky MG, Sharipova D, Farma JM, Reddy SS, Litwin S, Devarajan K, Campos AR, Yu Y, Schwartz B, von Mehren M, Rink L. Combined Inhibition of AKT and KIT Restores Expression of Programmed Cell Death 4 (PDCD4) in Gastrointestinal Stromal Tumor. Cancers. 13. PMID 34359600 DOI: 10.3390/cancers13153699  0.37
2020 Ye S, Sharipova D, Kozinova M, Klug LR, D'Souza JW, Belinsky MG, Johnson KJ, Einarson MB, Devarajan K, Zhou Y, Litwin S, Heinrich MC, DeMatteo RP, von Mehren M, Duncan JS, ... Rink L, et al. Identification of Wee1 as target in combination with avapritinib for Gastrointestinal Stromal Tumor treatment. Jci Insight. PMID 33320833 DOI: 10.1172/jci.insight.143474  0.436
2014 Atay S, Banskota S, Crow J, Sethi G, Rink L, Godwin AK. Oncogenic KIT-containing exosomes increase gastrointestinal stromal tumor cell invasion. Proceedings of the National Academy of Sciences of the United States of America. 111: 711-6. PMID 24379393 DOI: 10.1073/Pnas.1310501111  0.31
2009 Ochs MF, Rink L, Tarn C, Mburu S, Taguchi T, Eisenberg B, Godwin AK. Detection of treatment-induced changes in signaling pathways in gastrointestinal stromal tumors using transcriptomic data Cancer Research. 69: 9125-9132. PMID 19903850 DOI: 10.1158/0008-5472.Can-09-1709  0.3
2008 Tarn C, Rink L, Merkel E, Flieder D, Pathak H, Koumbi D, Testa JR, Eisenberg B, von Mehren M, Godwin AK. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proceedings of the National Academy of Sciences of the United States of America. 105: 8387-92. PMID 18550829 DOI: 10.1073/pnas.0803383105  0.352
2007 Rink L, Slupianek A, Stoklosa T, Nieborowska-Skorska M, Urbanska K, Seferynska I, Reiss K, Skorski T. Enhanced phosphorylation of Nbs1, a member of DNA repair/checkpoint complex Mre11-RAD50-Nbs1, can be targeted to increase the efficacy of imatinib mesylate against BCR/ABL-positive leukemia cells. Blood. 110: 651-60. PMID 17431132 DOI: 10.1182/Blood-2006-08-042630  0.641
2006 Nieborowska-Skorska M, Stoklosa T, Datta M, Czechowska A, Rink L, Slupianek A, Koptyra M, Seferynska I, Krszyna K, Blasiak J, Skorski T. ATR-Chk1 axis protects BCR/ABL leukemia cells from the lethal effect of DNA double-strand breaks. Cell Cycle (Georgetown, Tex.). 5: 994-1000. PMID 16687921 DOI: 10.4161/Cc.5.9.2722  0.696
2006 Nieborowska-Skorska M, Hoser G, Rink L, Malecki M, Kossev P, Wasik MA, Skorski T. Id1 transcription inhibitor-matrix metalloproteinase 9 axis enhances invasiveness of the breakpoint cluster region/abelson tyrosine kinase-transformed leukemia cells. Cancer Research. 66: 4108-16. PMID 16618731 DOI: 10.1158/0008-5472.Can-05-1584  0.552
2006 Rink L, Stoklosa T, Nieborowska-Skorska M, Slupianek A, Seferynska I, Skorski T. Enhanced Phosphorylation of Nbs1, a Member of DNA Repair/Checkpoint Complex RAD50-Mre11-Nbs1, Can Be Targeted Simultaneously with BCR/ABL Kinase To Eliminate Leukemia Cells. Blood. 108: 2127-2127. DOI: 10.1182/Blood.V108.11.2127.2127  0.679
2005 Nieborowska M, Stoklosa T, Datta M, Czechowska A, Rink L, Blasiak J, Skorski T. ATR-Chk1 Axis Is Activated, but the Function of Chk1 Is Disrupted in BCR/ABL Leukemia Cells Responding to DNA Damage. Blood. 106: 2883-2883. DOI: 10.1182/Blood.V106.11.2883.2883  0.675
Show low-probability matches.